Zur Kurzanzeige

2024-02-22Zeitschriftenartikel
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
dc.contributor.authorMaurel, Marine
dc.contributor.authorHoward, Jennifer
dc.contributor.authorKissling, Esther
dc.contributor.authorPozo, Francisco
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorBuda, Silke
dc.contributor.authorSève, Noémie
dc.contributor.authorMcKenna, Adele
dc.contributor.authorMeijer, Adam
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorTúri, Gergő
dc.contributor.authorLazăr, Mihaela
dc.contributor.authorMazagatos, Clara
dc.contributor.authorEcheverria, Aitziber
dc.contributor.authorAbela, Stephen
dc.contributor.authorBourgeois, Marc
dc.contributor.authorMachado, Ausenda
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorPetrović, Goranka
dc.contributor.authorBeatrix
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorJancoriene, Ligita
dc.contributor.authorMarin, Alexandru
dc.contributor.authorHusa, Petr
dc.contributor.authorDuffy, Roisin
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorGallardo García, Virtudes
dc.contributor.authorGoerlitz, Luise
dc.contributor.authorEnouf, Vincent
dc.contributor.authorBennett, Charlene
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorTrobajo-Sanmartín, Camino
dc.contributor.authorVišekruna Vučina, Vesna
dc.contributor.authorSamuelsson Hagey, Tove
dc.contributor.authorLameiras Azevedo, Ana Sofía
dc.contributor.authorCastilla, Jesús
dc.contributor.authorXuereb, Gerd
dc.contributor.authorDelaere, Bénédicte
dc.contributor.authorGómez, Verónica
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorBacci, Sabrina
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorRose, Angela M. C.
dc.contributor.authoron behalf of the European IVE group
dc.date.accessioned2026-04-27T10:21:12Z
dc.date.available2026-04-27T10:21:12Z
dc.date.issued2024-02-22none
dc.identifier.other10.2807/1560-7917.ES.2024.29.8.2400089
dc.identifier.urihttp://edoc.rki.de/176904/13680
dc.description.abstractInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectEuropeeng
dc.subjectinfluenzaeng
dc.subjectmulticentre studyeng
dc.subjecttest-negative designeng
dc.subjectvaccine effectivenesseng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleInterim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024none
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/13680-2
dc.type.versionpublishedVersionnone
local.edoc.container-titleEurosurveillance - Europe's journal on infectious disease surveillance, epidemiology, prevention and controlnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-publisher-nameEuropean Centre for Disease Prevention and Controlnone
local.edoc.container-reportyear2024none
local.edoc.container-firstpage1none
local.edoc.container-lastpage8none
dc.description.versionPeer Reviewednone

Zur Kurzanzeige